Blinatumomab (Blincyto)

From - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Bi-specific T-cell engager (BiTE) antibody that targets CD19 (expressed on B cells) and CD3 (expressed on T cells).[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: MT103, AMG 103
  • Brand name: Blincyto


  1. 1.0 1.1 1.2 Blinatumomab (Blincyto) package insert
  2. Blinatumomab (Blincyto) package insert (locally hosted backup)
  3. Blincyto manufacturer's website
  4. Blinatumomab (Blincyto) patient drug information (Chemocare)
  5. Blinatumomab (Blincyto) patient drug information (UpToDate)